CJC-1295 + Ipamorelin 10 mg

What is CJC-1295 + Ipamorelin?

This product combines two synthetic peptides from different families in one shared, freeze-dried vial. CJC-1295 is an analogue of growth-hormone-releasing hormone (GHRH), Ipamorelin a pentapeptide from the group of growth-hormone-releasing peptides (GHRP). Because both substances are present in the same lyophilisate, this is a blend and not a set of two vials. The product name gives both components, and the figure of 10 mg refers to their sum.

Two components, two peptide families

• CJC-1295 is based on the fragment GRF(1-29), the first 29 amino acids of human GHRH. Four positions are substituted (D-Ala2, Gln8, Ala15, Leu27), and the C-terminus is present as an amide. With a mass of over 3300 g/mol, CJC-1295 is by far the larger partner.
• Ipamorelin comprises only five building blocks: Aib-His-D-2-Nal-D-Phe-Lys-NH2, molecular formula C38H49N9O5, 711.9 g/mol, CAS 170851-70-4. With Aib, D-2-naphthylalanine and D-phenylalanine it contains no fewer than three non-proteinogenic building blocks.

CJC-1295 is almost five times as heavy as Ipamorelin, and the two molecules go back to independent sequence lines: CJC-1295 to endogenous GHRH, Ipamorelin to a series of GHRP-1 modifications lacking its central Ala-Trp motif.

Which form of CJC-1295? With and without DAC

The name CJC-1295 is ambiguous. In the original scientific literature it denotes a form with a drug affinity complex (DAC), in which an additional lysine with a maleimidopropionyl group sits at the C-terminus for coupling to albumin. In the research-chemical trade, by contrast, “CJC-1295 no DAC” stands for the chain without this attachment, also known as Mod GRF(1-29). The two forms are around 279 Da apart and can be assigned unambiguously by mass spectrometry:

• without DAC: C152H252N44O42, 3367.9 g/mol
• with DAC: C165H269N47O46, 3647.2 g/mol

As a single substance, the catalogue lists CJC-1295 (No DAC).

Classification and research context

CJC-1295 and Ipamorelin belong to the growth hormone axis between the hypothalamus and the pituitary, but they target different receptors there: CJC-1295 the GHRH receptor of the anterior pituitary, Ipamorelin the GH secretagogue receptor, also referred to as the ghrelin receptor (GHS-R1a). In research catalogues the two often appear as a pair because they represent two separate receptor systems of the same axis. They are studied in in-vitro assays with pituitary cells and in preclinical animal models, among other things on pharmacokinetics. The single substance Ipamorelin and the GHRH analogue Tesamorelin are listed in the GHRH & GHRP category.

Analytics at GPeptides

For the blend, the analytics have to capture both peptides side by side. HPLC separates the short and the long chain into signals of their own. Mass spectrometry detects Ipamorelin at around 712 Da and assigns the CJC-1295 component, by its mass, to the form with or without DAC; large peptides of this kind typically appear as multiply charged ions, from which the molecular mass is back-calculated. The product is regularly tested by an independent external laboratory using HPLC and mass spectrometry. Available certificates of analysis are in the lab area; where no certificate is available yet, the testing is marked as pending.